NO20072051L - Nye pyrimidinderivater og deres anvendelse som PPAR-alfa modulatorar - Google Patents

Nye pyrimidinderivater og deres anvendelse som PPAR-alfa modulatorar

Info

Publication number
NO20072051L
NO20072051L NO20072051A NO20072051A NO20072051L NO 20072051 L NO20072051 L NO 20072051L NO 20072051 A NO20072051 A NO 20072051A NO 20072051 A NO20072051 A NO 20072051A NO 20072051 L NO20072051 L NO 20072051L
Authority
NO
Norway
Prior art keywords
pyrimidine derivatives
ppar
novel pyrimidine
alpha modulators
therapy
Prior art date
Application number
NO20072051A
Other languages
English (en)
Norwegian (no)
Inventor
Hilmar Bischoff
Klemens Lustig
Claudia Hirth-Dietrich
Elke Dittrich-Wengenroth
Armin Kern
Ulrich Rosentreter
Dieter Lang
Lars Barfacker
Axel Kretschmer
Peter Ellinghaus
Martin Raabe
Christian Pilger
Stephan Bartel
Marcus Bauser
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of NO20072051L publication Critical patent/NO20072051L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
NO20072051A 2004-09-25 2007-04-20 Nye pyrimidinderivater og deres anvendelse som PPAR-alfa modulatorar NO20072051L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004046623A DE102004046623A1 (de) 2004-09-25 2004-09-25 Neue Pyrimidin-Derivate und ihre Verwendung
PCT/EP2005/009734 WO2006032384A1 (fr) 2004-09-25 2005-09-10 Nouveaux derives de pyrimidine et leur utilisation comme modulateurs de ppar-alpha

Publications (1)

Publication Number Publication Date
NO20072051L true NO20072051L (no) 2007-06-07

Family

ID=35063041

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072051A NO20072051L (no) 2004-09-25 2007-04-20 Nye pyrimidinderivater og deres anvendelse som PPAR-alfa modulatorar

Country Status (22)

Country Link
US (1) US20080261990A1 (fr)
EP (1) EP1797045A1 (fr)
JP (1) JP2008514559A (fr)
KR (1) KR20070055621A (fr)
CN (1) CN101065364A (fr)
AR (1) AR051295A1 (fr)
AU (1) AU2005287589A1 (fr)
BR (1) BRPI0517327A (fr)
CA (1) CA2582492A1 (fr)
DE (1) DE102004046623A1 (fr)
EC (1) ECSP077340A (fr)
GT (1) GT200500266A (fr)
IL (1) IL182136A0 (fr)
MA (1) MA28882B1 (fr)
MX (1) MX2007003428A (fr)
NO (1) NO20072051L (fr)
PE (1) PE20060657A1 (fr)
RU (1) RU2007115215A (fr)
SV (1) SV2007002235A (fr)
TW (1) TW200628451A (fr)
UY (1) UY29127A1 (fr)
WO (1) WO2006032384A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2155195B1 (fr) 2007-04-13 2014-07-16 Millennium Pharmaceuticals, Inc. Combinaison d'une thérapie anticoagulante à un composé agissant en tant qu'inhibiteur de facteur Xa
KR100813387B1 (ko) * 2007-06-26 2008-03-12 신명곤 부형제 첨가없이 인삼농축액으로 유동성 및 저장성이우수한 인삼농축액환 제조 방법
EP4137137A1 (fr) 2010-05-26 2023-02-22 Satiogen Pharmaceuticals, Inc. Inhibiteurs et satiogènes de recyclage d'acide biliaire pour le traitement du diabète, de l'obésité et d'états gastro-intestinaux inflammatoires
CN103298469A (zh) 2010-08-31 2013-09-11 首尔大学校产学协力财团 PPARδ激动剂的胎儿重编程的用途
EA038594B1 (ru) 2011-10-28 2021-09-21 Шайр Хьюман Дженетик Терапис, Инк. Ингибиторы рециркуляции желчных кислот для лечения гиперхолемии и холестатического заболевания печени
JP6217938B2 (ja) 2011-10-28 2017-10-25 ルメナ ファーマシューティカルズ エルエルシー 小児の胆汁うっ滞性肝疾患の処置のための胆汁酸再循環阻害剤
CN103130732A (zh) * 2011-11-22 2013-06-05 上海博康精细化工有限公司 3,5-二甲基-4-氯甲基异噁唑的制备方法
KR20160002773A (ko) 2013-03-15 2016-01-08 루메나 파마수티컬즈, 인코포레이티드 원발성 담관염 및 염증성 장 질환 치료용 담즙산 재순환 억제제
AU2014229050A1 (en) 2013-03-15 2015-10-22 Lumena Pharmaceuticals Llc Bile acid recycling inhibitors for treatment of Barrett's esophagus and gastroesophageal reflux disease
US10981899B2 (en) 2016-04-28 2021-04-20 Cornell University Inhibitors of soluble adenylyl cyclase
EP4424363B1 (fr) 2019-02-12 2026-04-29 Mirum Pharmaceuticals, Inc. Procédés pour augmenter la croissance chez des sujets pédiatriques présentant une maladie hépatique cholestatique
CN115598267B (zh) * 2022-12-13 2023-05-09 山东省食品药品检验研究院 一种格列齐特中潜在遗传毒性杂质的分析方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20010795A2 (en) * 1999-04-28 2003-02-28 Aventis Pharma Gmbh Di-aryl acid derivatives as ppar receptor ligands
GB0214254D0 (en) * 2002-06-20 2002-07-31 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
AU2005287589A1 (en) 2006-03-30
MA28882B1 (fr) 2007-09-03
PE20060657A1 (es) 2006-08-12
JP2008514559A (ja) 2008-05-08
EP1797045A1 (fr) 2007-06-20
ECSP077340A (es) 2007-04-26
WO2006032384A1 (fr) 2006-03-30
CA2582492A1 (fr) 2006-03-30
CN101065364A (zh) 2007-10-31
KR20070055621A (ko) 2007-05-30
US20080261990A1 (en) 2008-10-23
IL182136A0 (en) 2007-07-24
AR051295A1 (es) 2007-01-03
TW200628451A (en) 2006-08-16
DE102004046623A1 (de) 2006-03-30
MX2007003428A (es) 2008-03-13
SV2007002235A (es) 2007-03-20
GT200500266A (es) 2006-05-11
BRPI0517327A (pt) 2008-10-07
UY29127A1 (es) 2006-04-28
RU2007115215A (ru) 2008-11-10

Similar Documents

Publication Publication Date Title
NO20050579L (no) Indolinfenylsulfonamidderivater
ECSP077357A (es) Procedimiento para la preparación de 4-{4-[cloro-3-(trifluorometil) fenil] amino}carbonil)amino]fenoxi}n-metilpiridina-2-carboxamida
NO20051726L (no) Pyrimidinonderivaer som terapeutiske midler ovenfor akutte og kroniske inflammasjons-, iskemiske og remodeleringsprosesser
NO20080164L (no) N-(pyridin-2-yl)-sulfonamidderivater
NO20064584L (no) Tetrahydropyridoindolderivater
NO20063925L (no) Indazolderivater som inhibitorer av hormonsensitiv lipase
NO20081482L (no) Delta- og epsilon-krystallformer for imatinibmesylat
NO20082269L (no) Nye piperaziner som antimalariamidler
NO20065904L (no) Terapeutiske forbindelser
ECSP077340A (es) Nuevos derivados de pirimidina y su uso como moduladores del ppar-alfa
NO20071300L (no) Trifluormetylsubstituerte benzamider som kinaseinhibitorer.
NO20082986L (no) Nye, acylisk substituerte furopyrimidinderivater og anvendelse derav for behandling av kardiovaskulaere lidelser
NO20064347L (no) Substituerte 1,2,3,4-tetrahydroisokinolinderivater
NO20071504L (no) Pyrimidinderivanter.
NO20071074L (no) Substituerte cykliske ureaderivater, fremstilling derav og farmasoytisk anvendelse derav som kinaseinhibitorer
NO20060981L (no) Pyridazinderivater og deres anvendelse som terapeutiske midler
NO20072978L (no) Nye betuinderivater, preparat derav og anvendelse derav
NO20073059L (no) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
NO20081942L (no) Karbamoylbenzotriazolderivater som inhibitorer av lipaser og fosfolipaser
NO20052028L (no) Pyridinderivater som CB2 reseptor modulatorer
NO20062923L (no) Nye benzofuranderivater som kan anvendes i forebygging eller behandling av 5-HT6 reseptorrelatert forstyrrelse
NO20090328L (no) Nye forbindelser 385
NO20083905L (no) Nye pyron-indol derivater og fremgangsmate for deres fremstilling
NO20082112L (no) 3-Amino-2-arylpropylazaindoler og deres anvendelse
TW200621765A (en) Substituted phenylaminothiazoles and their use

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application